Lyophilisomes as a new generation of drug delivery capsules

International Journal of Pharmaceutics

Volumn 439, Issue 1-2, 2012, Pages 127-135

  Van Bracht, Etienne ^a   Raavé, René ^a   Verdurmen, Wouter P R ^a   Wismans, Ronnie G ^a   Geutjes, Paul J ^a   Brock, Roland E ^a   Oosterwijk, Egbert ^a   Van Kuppevelt, Toin H ^a   Daamen, Willeke F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Albumin; Cancer; Curcumin; Doxorubicin; Drug delivery; Nano micro particles

Indexed keywords

ALBUMIN; CURCUMIN; DOXORUBICIN; LYOPHILISOME; NANOCAPSULE; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG DELIVERY SYSTEM; DRUG RELEASE; FEMALE; FREEZE DRYING; FREEZING; HELA CELL; HUMAN; HUMAN CELL; MICROCAPSULE; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ALBUMINS; ANTINEOPLASTIC AGENTS; CAPSULES; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FREEZE DRYING; FREEZING; HUMANS;

EID: 84868254976     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.10.008     Document Type: Article

References (45)

1. B.B. Aggarwal, A. Kumar, and A.C. Bharti Anticancer potential of curcumin: preclinical and clinical studies Anticancer Res. 23 2003 363 398
2. Y.C. Barenholz Doxil(R) - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134
3. D. Bellarosa, A. Ciucci, A. Bullo, F. Nardelli, S. Manzini, C.A. Maggi, and C. Goso Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines J. Pharmacol. Exp. Ther. 296 2001 276 283
4. S. Bisht, G. Feldmann, S. Soni, R. Ravi, C. Karikar, A. Maitra, and A. Maitra Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy J. Nanobiotechnol. 5 2007 3
5. J. Bouma, J.H. Beijnen, A. Bult, and W.J. Underberg Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties Pharm. Weekbl. Sci. 8 1986 109 133
6. I. Brouet, and H. Ohshima Curcumin, an anti-tumour promoter and anti-inflammatory agent inhibits induction of nitric oxide synthase in activated macrophages Biochem. Biophys. Res. Commun. 206 1995 533 540
7. J.D. Byrne, T. Betancourt, and L. Brannon-Peppas Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Deliv. Rev. 60 2008 1615 1626
8. W.F. Daamen, P.J. Geutjes, S.T.M. Nillesen, H.Th.B. Van Moerkerk, R. Wismans, T. Hafmans, L.P.W.J. Van den Heuvel, A.M.A. Pistorius, J.H. Veerkamp, J.C.M. Van Hest, and T.H. Van Kuppevelt Lyophilisomes: a new type of (bio)capsules Adv. Mater. 19 2007 673 677
9. R.K. Das, N. Kasoju, and U. Bora Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells Nanomedicine 6 2010 153 160
10. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. Ferrari Size and shape effects in the biodistribution of intravascularly injected particles J. Control. Release 141 2010 320 327
11. S. Dreis, F. Rothweiler, M. Michaelis, J. Cinatl Jr.; J. Kreuter, and K. Langer Preparation characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles Int. J. Pharm. 341 2007 207 214
12. A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato, and M. Diederich Chemopreventive and therapeutic effects of curcumin Cancer Lett. 223 2005 181 190
13. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Albumin-based nanoparticles as potential controlled release drug delivery systems J. Control. Release 157 2012 168 182
14. A.O. Elzoghby, W.M. Samy, and N.A. Elgindy Protein-based nanocarriers as promising drug and gene delivery systems J. Control. Release 161 2012 38 49
15. M. Fasano, S. Curry, E. Terreno, M. Galliano, G. Fanali, P. Narciso, S. Notari, and P. Ascenzi The extraordinary ligand binding properties of human serum albumin IUBMB Life 57 2005 787 796
16. S.B. Feinstein, J. Cheirif, F.J. Ten Cate, P.R. Silverman, P.A. Heidenreich, C. Dick, R.M. Desir, W.F. Armstrong, M.A. Quinones, and P.M. Shah Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results J. Am. Coll. Cardiol. 16 1990 316 324
17. A. Fritze, F. Hens, A. Kimpfler, R. Schubert, and R. Peschka-Suss Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient Biochim. Biophys. Acta 1758 2006 1633 1640
18. E. Garza-Licudine, D. Deo, S. Yu, A. Uz-Zaman, and W.B. Dunbar Portable nanoparticle quantization using a resizable nanopore instrument - the IZON qNano Conf. Proc. IEEE Eng. Med. Biol. Soc. 2010 2010 5736 5739
19. M. Gaumet, A. Vargas, R. Gurny, and F. Delie Nanoparticles for drug delivery: the need for precision in reporting particle size parameters Eur. J. Pharm. Biopharm. 69 2008 1 9
20. B. Geny, B. Mettauer, B. Muan, P. Bischoff, E. Epailly, F. Piquard, B. Eisenmann, and P. Haberey Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients J. Am. Coll. Cardiol. 22 1993 1193 1198
21. H. Hatcher, R. Planalp, J. Cho, F.M. Torti, and S.V. Torti Curcumin: from ancient medicine to current clinical trials Cell Mol. Life Sci. 65 2008 1631 1652
22. M.J. Hawkins, P. Soon-Shiong, and N. Desai Protein nanoparticles as drug carriers in clinical medicine Adv. Drug Deliv. Rev. 60 2008 876 885
23. R.D. Hofheinz, S.U. Gnad-Vogt, U. Beyer, and A. Hochhaus Liposomal encapsulated anti-cancer drugs Anticancer Drugs 16 2005 691 707
24. N.K. Ibrahim, N. Desai, S. Legha, P. Soon-Shiong, R.L. Theriault, E. Rivera, B. Esmaeli, S.E. Ring, A. Bedikian, G.N. Hortobagyi, and J.A. Ellerhorst Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin. Cancer Res. 8 2002 1038 1044
25. N.K. Ibrahim, B. Samuels, R. Page, D. Doval, K.M. Patel, S.C. Rao, M.K. Nair, P. Bhar, N. Desai, and G.N. Hortobagyi Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J. Clin. Oncol. 23 2005 6019 6026
26. Y. Kaminaga, A. Nagatsu, T. Akiyama, N. Sugimoto, T. Yamazaki, T. Maitani, and H. Mizukami Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus FEBS Lett. 555 2003 311 316
27. A.J. Klein-Szanto Carcinogenic effects of chemotherapeutic compounds Prog. Clin. Biol. Res. 374 1992 167 174
28. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
29. T. Lammers, W.E. Hennink, and G. Storm Tumour-targeted nanomedicines: principles and practice Br. J. Cancer 99 2008 392 397
30. L. Li, F.S. Braiteh, and R. Kurzrock Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis Cancer 104 2005 1322 1331
31. R.M. Lowenthal, and K. Eaton Toxicity of chemotherapy Hematol. Oncol. Clin. North Am. 10 1996 967 990
32. R.K. Maheshwari, A.K. Singh, J. Gaddipati, and R.C. Srimal Multiple biological activities of curcumin: a short review Life Sci. 78 2006 2081 2087
33. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
34. S.M. Moghimi, A.C. Hunter, and J.C. Murray Nanomedicine: current status and future prospects FASEB J. 19 2005 311 330
35. A. Mukerjee, and J.K. Vishwanatha Formulation characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy Anticancer Res. 29 2009 3867 3875
36. K.L. Nair, A.K. Thulasidasan, G. Deepa, R.J. Anto, and G.S. Kumar Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier Int. J. Pharm. 425 2012 44 52
37. N. Osheroff, A.H. Corbett, and M.J. Robinson Mechanism of action of topoisomerase II-targeted antineoplastic drugs Adv. Pharmacol. 29B 1994 105 126
38. R. Savla, O. Taratula, O. Garbuzenko, and T. Minko Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer J. Control. Release 153 2011 16 22
39. A. Sawaya, J.P. Benoit, and S. Benita Binding mechanism of doxorubicin in ion-exchange albumin microcapsules J. Pharm. Sci. 76 1987 475 480
40. S. Shishodia, G. Sethi, and B.B. Aggarwal Curcumin: getting back to the roots Ann. N.Y. Acad. Sci. 1056 2005 206 217
41. V. Torchilin Tumor delivery of macromolecular drugs based on the EPR effect Adv. Drug Deliv. Rev. 63 2011 131 135
42. V.P. Torchilin Passive and active drug targeting: drug delivery to tumors as an example Handb. Exp. Pharmacol. 2010 3 53
43. R.C. Young, R.F. Ozols, and C.E. Myers The anthracycline antineoplastic drugs N. Engl. J. Med. 305 1981 139 153
44. P. Yousefpour, F. Atyabi, E. Vasheghani-Farahani, A.A. Movahedi, and R. Dinarvand Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab Int. J. Nanomedicine 6 2011 1977 1990
45. J.A. Zhang, and J. Pawelchak Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditions. Part 1: lipid hydrolysis Eur. J. Pharm. Biopharm. 50 2000 357 364